Evidence map›Paper›PMID 26033922›Full record

Observational studyJournal of diabetes science and technology2015

Multicenter Observational Study of the First-Generation Intravenous Blood Glucose Monitoring System in Hospitalized Patients.

Grant V Bochicchio, Brian R Hipszer, Michelle F Magee, Richard M Bergenstal, Anthony P Furnary, Angela M Gulino, Michael J Higgins, Peter C Simpson, Jeffrey I Joseph

Open access · bronzeAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of diabetes science and technology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Grant V BochicchioWashington University School of Medicine, St. Louis, MO, USA.
Brian R HipszerEdwards Lifesciences, Irvine, CA, USA.
Michelle F MageeGeorgetown University, Washington Hospital Center, Washington, DC, USA.
Richard M BergenstalInternational Diabetes Center, Methodist Hospital, Minneapolis, MN, USA.
Anthony P FurnaryStarr-Wood Cardiac Group, Providence Heart and Vascular Institute, Portland, OR, USA.
Angela M GulinoEdwards Lifesciences, Irvine, CA, USA.
Michael J HigginsEdwards Lifesciences, Irvine, CA, USA.
Peter C SimpsonDexcom, San Diego, CA, USA.
Jeffrey I JosephThomas Jefferson University, Philadelphia, PA, USA Jeffrey.Joseph@Jefferson.edu.
Edwards Lifesciences (United States) · USDexcom (United States) · USGeorgetown University · USMethodist Hospital · USProvidence College · USThomas Jefferson University · USWashington University in St. Louis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCurrent methods of blood glucose (BG) monitoring and insulin delivery are labor intensive and commonly fail to achieve the desired level of BG control. There is great clinical need in the hospital for a user-friendly bedside device that can automatically monitor the concentration of BG safely, accurately, frequently, and reliably.

methodsA 100-patient observation study was conducted at 6 US hospitals to evaluate the first generation of the Intravenous Blood Glucose (IVBG) System (Edwards Lifesciences LLC & Dexcom Inc). Device safety, accuracy, and reliability were assessed. A research nurse sampled blood from a vascular catheter every 4 hours for ≤ 72 hours and BG concentration was measured using the YSI 2300 STAT Plus Analyzer (YSI Life Sciences). The IVBG measurements were compared to YSI measurements to calculate point accuracy.

resultsThe IVBG systems logged more than 5500 hours of operation in 100 critical care patients without causing infection or inflammation of a vein. A total of 44135 IVBG measurements were performed in 100 patients with 30231 measurements from the subset of 75 patients used for accuracy analysis. In all, 996 IVBG measurements were time-matched with reference YSI measurements. These pairs had a mean absolute difference (MAD) of 11.61 mg/dl, a mean absolute relative difference (MARD) of 8.23%, 93% met 15/20% accuracy defined by International Organization for Standardization 15197:2003 standard, and 93.2% were in zone A of the Clarke error grid. The IVBG sensors were exposed to more than 200 different medications with no observable effect on accuracy.

conclusionsThe IVBG system is an automated and user-friendly glucose monitoring system that provides accurate and frequent BG measurements with great potential to improve the safety and efficacy of insulin therapy and BG control in the hospital, potentially leading to improved clinical outcomes.

Indexed as

Insulin Infusion SystemsAdultAgedAutomationBlood GlucoseCalibrationCatheterizationEquipment DesignFemaleHospitalizationHumansInfusion Pumps, ImplantableInfusions, IntravenousMaleMiddle AgedMonitoring, PhysiologicBlood Glucoseaccuracycritical care glucose monitoringglucose sensorIntravenous Blood Glucose (IVBG) systemnear-continuous glucose monitoring systemsafety

Identifiers

PMID26033922
PMCPMC4525650
OpenAlexW1810606367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.